Abstract

The tumor microenvironment is an important aspect of cancer biology that contributes to tumor initiation, tumor progression and responses to therapy. The composition and characteristics of the tumor microenvironment vary widely and are important in determining the anti-tumor immune response. Successful immunization requires activation of both innate and adaptive immunity. Generally, immune system is compromised in patients with cancer due to immune suppression, loss of tumor antigen expression and dysfunction of antigen presenting cells (APC). Thus, therapeutic immunization leading to cancer regression remains a significant challenge. Certain cells of the immune system, including dendritic cells (DCs) and gamma delta (γδ) T cells are capable of driving potent anti-tumor responses. The property of MHC-unrestricted cytotoxicity, high potential of cytokine release, tissue tropism and early activation in infections and malignant disease makes γδ T cells as an emerging candidate for immunotherapy. Various strategies are being developed to enhance anti-tumor immune responses of γδ T cells and DCs one of them is the use of novel adjuvants like toll like receptors (TLR) agonists, which enhance γδ T cell function directly or through DC activation, which has ability to prime γδ T cells. TLR agonists are being used clinically either alone or in combination with tumor antigens and has shown initial success in both enhancing immune responses and eliciting anti-tumor activity. TLR activated γδ T cells and DCs nurture each other’s activation. This provides a potent base for first line of defense and manipulation of the adaptive response against pathogens and cancer. The available data provides a strong rationale for initiating combinatorial therapy for the treatment of diseases and this review will summarize the application of adjuvants (TLRs) for boosting immune response of γδ T cells to treat cancer and infectious diseases and their use in combinatorial therapy.

Highlights

  • Innate and adaptive immune responses are sentinels of host against the diverse repertoire of infectious agents and cancer

  • We summarize and discuss some of the recent advances of the γδ T cell biology and how direct control of γδ T lymphocyte function and activation is monitored by toll like receptors (TLR) receptors and ligands

  • We reported that γδ T cells from healthy individuals (HI) and oral cancer (OC) patients express higher levels of TLR2, TLR3, TLR4, and TLR9 than in αβT cells

Read more

Summary

INTRODUCTION

Innate and adaptive immune responses are sentinels of host against the diverse repertoire of infectious agents (viruses and bacteria) and cancer. Γδ T cells have several innate cell-like characters that allow their early and rapid activation following recognition of cellular stress and infection [4, 5] To accomplish these functions, γδ T cells use both the T cell receptor (TCR) and additional activating receptors (notably NKG2D, NOTCH, and TLR) to respond to stress-induced ligands and infection. The Vδ2+ cells derived from human cord blood showed early signs of activation. These cells secrete IFN-γ and express perforin after short-term in vitro stimulation [10].

TLRs modulate γδ T cells
Do not show tissue tropism αβ T Cells response is late
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call